Literature DB >> 7682572

Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. A possible mechanism for the acute attack of variegate porphyria.

P Meissner1, P Adams, R Kirsch.   

Abstract

Variegate porphyria (VP) is characterized by photocutaneous lesions and acute neuropsychiatric attacks. Decreased protoporphyrinogen oxidase activity results in accumulation of protoporphyrin (ogen) IX and coproporphyrin (ogen) III. During acute attacks delta-aminolevulinic acid and porphobilinogen also increase, suggesting that porphobilinogen deaminase (PBG-D) may be rate limiting. We have examined the effects of porphyrinogens accumulating in VP on PBG-D activity in Epstein-Barr virus-transformed lymphoblast sonicates from 12 VP and 12 control subjects. Protoporphyrinogen oxidase activity was decreased and protoporphyrin increased in VP lymphoblasts. PBG-D in control lymphoblasts obeyed Michaelis-Menten kinetics (Vmax 28.7 +/- 1.8 pmol/mg per h, Hill coefficient 0.83 +/- 0.07). VP sonicates yielded sigmoidal substrate-velocity curves that did not obey Michaelis-Menten kinetics. Vmax was decreased (21.2 +/- 2.0 pmol/mg per h) and the Hill coefficient was 1.78 +/- 0.17. Addition of protoporphyrinogen IX and coproporphyrinogen III to control sonicates yielded sigmoidal PBG-D substrate-velocity curves and decreased PBG-D Vmax. Addition of porphyrins or uroporphyrinogen III did not affect PBG-D activity. Removal of endogenous porphyrin (ogens) from VP sonicates restored normal PBG-D kinetics. Purified human erythrocyte PBG-D obeyed Michaelis-Menten kinetics (Vmax 249 +/- 36 nmol/mg per h, Km 8.9 +/- 1.5 microM, Hill coefficient 0.93 +/- 0.14). Addition of protoporphyrinogen yielded a sigmoidal curve with decreased Vmax. The Hill coefficient approached 4. These findings provide a rational explanation for the increased delta-aminolevulinic acid and porphobilinogen during acute attacks of VP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682572      PMCID: PMC288118          DOI: 10.1172/JCI116348

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Protoporphyrinogen oxidase and porphobilinogen deaminase in variegate porphyria.

Authors:  P N Meissner; R S Day; M R Moore; P B Disler; E Harley
Journal:  Eur J Clin Invest       Date:  1986-06       Impact factor: 4.686

Review 2.  Biosynthesis of the pigments of life.

Authors:  A R Battersby
Journal:  J Nat Prod       Date:  1988 Jul-Aug       Impact factor: 4.050

3.  Evidence for a dipyrromethane cofactor at the catalytic site of E. coli porphobilinogen deaminase.

Authors:  P M Jordan; M J Warren
Journal:  FEBS Lett       Date:  1987-12-10       Impact factor: 4.124

4.  Porphyrin biosynthesis. VI. Separation and purification of porphobilinogen deaminase and uroporphyrinogen isomerase from cow liver. Porphobilinogenase an allosteric enzyme.

Authors:  H A Sancovich; A M Battle; M Grinstein
Journal:  Biochim Biophys Acta       Date:  1969-09-30

5.  Intracellular activity of HPRT Cape Town: purine uptake and growth of cultured cells in selective media.

Authors:  L M Steyn; E H Harley
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

Review 6.  Porphyria--the UCT experience.

Authors:  P N Meissner; D M Meissner; E D Sturrock; B Davidson; R E Kirsch
Journal:  S Afr Med J       Date:  1987-12-05

Review 7.  Porphyria cutanea tarda.

Authors:  N R Pimstone
Journal:  Semin Liver Dis       Date:  1982-05       Impact factor: 6.115

8.  Porphobilinogen deaminase: methods and principles of the enzymatic assay.

Authors:  P M Anderson; R J Desnick
Journal:  Enzyme       Date:  1982

9.  Purification of human erythrocyte porphobilinogen deaminase.

Authors:  A V Corrigall; P N Meissner; R E Kirsch
Journal:  S Afr Med J       Date:  1991-09-21

10.  Human red cell porphobilinogen deaminase. A simpler method of purification and some unusual properties.

Authors:  S A Fumagalli; M L Kotler; M V Rossetti; A M Batlle
Journal:  Int J Biochem       Date:  1985
View more
  11 in total

1.  Celiac disease in patients with variegate porphyria.

Authors:  S Twaddle; W S Wassif; A C Deacon; T J Peters
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

2.  Mapping of the variegate porphyria (VP) gene: contradictory evidence for linkage between VP and microsatellite markers at chromosome 14q32.

Authors:  L Warnich; P N Meissner; R J Hift; J H Louw; C J van Heerden; A E Retief
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

Review 3.  [Porphyrias-what is verified?]

Authors:  U Stölzel; I Kubisch; T Stauch
Journal:  Internist (Berl)       Date:  2018-12       Impact factor: 0.743

Review 4.  Erythropoietic and hepatic porphyrias.

Authors:  U Gross; G F Hoffmann; M O Doss
Journal:  J Inherit Metab Dis       Date:  2000-11       Impact factor: 4.982

Review 5.  The acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

Review 6.  Acute hepatic porphyrias: Current diagnosis & management.

Authors:  Karl E Anderson
Journal:  Mol Genet Metab       Date:  2019-07-05       Impact factor: 4.797

Review 7.  Dominant versus recessive: molecular mechanisms in metabolic disease.

Authors:  Johannes Zschocke
Journal:  J Inherit Metab Dis       Date:  2008-10-21       Impact factor: 4.982

Review 8.  Acute hepatic porphyria and anaesthesia: a practical approach to the prevention and management of acute neurovisceral attacks.

Authors:  N Wilson-Baig; M Badminton; D Schulenburg-Brand
Journal:  BJA Educ       Date:  2020-12-09

Review 9.  Novel treatment options for acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Curr Opin Gastroenterol       Date:  2021-05-01       Impact factor: 2.741

10.  Partial protoporphyrinogen oxidase (PPOX) gene deletions, due to different Alu-mediated mechanisms, identified by MLPA analysis in patients with variegate porphyria.

Authors:  Michela Barbaro; Maire Kotajärvi; Pauline Harper; Ylva Floderus
Journal:  Orphanet J Rare Dis       Date:  2013-01-16       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.